Latest & greatest articles for anticoagulation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on anticoagulation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on anticoagulation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for anticoagulation

341. Review: self monitoring increases the efficacy and safety of anticoagulant therapy Full Text available with Trip Pro

Review: self monitoring increases the efficacy and safety of anticoagulant therapy Review: self monitoring increases the efficacy and safety of anticoagulant therapy | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional (...) accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: self monitoring increases the efficacy and safety of anticoagulant therapy Article Text Therapeutics Review: self monitoring increases the efficacy and safety of anticoagulant therapy Free John Spandorfer , MD

2007 Evidence-Based Medicine

342. What is the optimal level of anticoagulation in adult patients receiving warfarin following implantation of a mechanical prosthetic mitral valve?

What is the optimal level of anticoagulation in adult patients receiving warfarin following implantation of a mechanical prosthetic mitral valve? BestBets: What is the optimal level of anticoagulation in adult patients receiving warfarin following implantation of a mechanical prosthetic mitral valve? What is the optimal level of anticoagulation in adult patients receiving warfarin following implantation of a mechanical prosthetic mitral valve? Report By: Andrew Bayliss, Peter Faber, Joel (...) (caged-ball) valves Overall similar to the ACCP recommendations although no comments on combination with aspirin or dipyridamole Lowe et al, 1999 Scotland Scottish Intercollegiate Guidelines Guidelines based on available cohort & RCT's (Level Ib-IV) Need for anticoagulation therapy Patients with mechanical heart valves require long-term warfarin therapy (level IIa, IIb, III evidence) Varying levels of evidence Significant amount of evidence remains "expert opinion" Recommendations for first

2007 BestBETS

343. WITHDRAWN: Anticoagulant and aspirin prophylaxis for preventing thromboembolism after major gynaecological surgery. (Abstract)

WITHDRAWN: Anticoagulant and aspirin prophylaxis for preventing thromboembolism after major gynaecological surgery. The reported overall risk of deep venous thrombosis in gynaecological surgery ranges from 7 to 45%. Fatal pulmonary embolism is estimated to occur in nearly 1% of these women. Pharmaceutical interventions are one possible prophylactic measure for preventing emboli in women undergoing major gynaecological surgery. Agents include unfractionated heparin (low -dose and adjusted-dose (...) , undergoing major gynaecological surgery and without contraindications to anticoagulants should be offered thromboprophylaxis. Evidence suggests that UH and LMWH are equally as effective in preventing DVT and the one trial available suggests that warfarin is as effective as UH. There is no evidence as yet to suggest that warfarin, heparin or aspirin reduce incidence of PE.

2007 Cochrane

344. WITHDRAWN: Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter. (Abstract)

WITHDRAWN: Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter. Atrial fibrillation (AF) carries a high risk of stroke and other thromboembolic events. Appropriate use of drugs to prevent thromboembolism in patients with AF involves comparing the patient's risk of stroke to the risk of hemorrhage from medication use.To quantify risk of stroke, major hemorrhage and death from using medications that have been rigorously evaluated for prevention

2007 Cochrane

345. Is short-term anticoagulation necessary after mitral valve repair?

Is short-term anticoagulation necessary after mitral valve repair? BestBets: Is short-term anticoagulation necessary after mitral valve repair? Is short-term anticoagulation necessary after mitral valve repair? Report By: Sanjay Asopa, Anish Patel - Specialist Registrars in Cardiothoracic Surgery Search checked by Joel Dunning - Cardiothoracic Registrar RCS Institution: Wessex Cardiothoracic Unit, Southampton General Hospital Date Submitted: 21st December 2006 Date Completed: 9th May 2007 Last (...) Carpentier reconstruction between 1980 and 1986. All patients were placed on warfarin on the third post-operative day. Warfarin was discontinued at the end of 3 months and patients were switched to antiplatelet therapy. High risk patients with predisposing factors were continued on warfarin long term basis Retrospective cohort study (level 2b) Long-term thrombo-embolic rates following mitral valve reconstruction. Of the 125 survivors without re-operation, (73 of 125) 58.4 % were on an anticoagulant

2007 BestBETS

346. Review: long term anticoagulation reduces recurrent venous thromboembolism

Review: long term anticoagulation reduces recurrent venous thromboembolism Review: long term anticoagulation reduces recurrent venous thromboembolism | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username (...) * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: long term anticoagulation reduces recurrent venous thromboembolism Article Text Therapeutics Review: long term anticoagulation reduces recurrent venous thromboembolism Statistics from Altmetric.com Request Permissions If you wish to reuse

2007 Evidence-Based Medicine

347. Brief communication: Preoperative anticoagulant activity after bridging low-molecular-weight heparin for temporary interruption of warfarin. (Abstract)

Brief communication: Preoperative anticoagulant activity after bridging low-molecular-weight heparin for temporary interruption of warfarin. Preoperative low-molecular-weight heparin (LMWH) is often used when warfarin therapy is interrupted for surgery.To determine the preoperative anticoagulant activity of LMWH following a standardized "bridging" regimen.Prospective cohort study.Single university hospital.Consecutive patients who had warfarin therapy interrupted before an invasive

2007 Annals of Internal Medicine

348. Long-acting anticoagulant rodenticide poisoning: an evidence-based consensus guideline for out-of-hospital management.

Long-acting anticoagulant rodenticide poisoning: an evidence-based consensus guideline for out-of-hospital management. Guidelines and Measures | Agency for Healthcare Research & Quality HHS.gov Search ahrq.gov Search ahrq.gov Menu Topics A - Z Healthcare Delivery Latest available findings on quality of and access to health care Searchable database of AHRQ Grants, Working Papers & HHS Recovery Act Projects AHRQ Projects funded by the Patient-Centered Outcomes Research Trust Fund You are here

2007 American Association of Poison Control Centers

349. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. Full Text available with Trip Pro

Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. Atherosclerotic peripheral arterial disease is associated with an increased risk of myocardial infarction, stroke, and death from cardiovascular causes. Antiplatelet drugs reduce this risk, but the role of oral anticoagulant agents in the prevention of cardiovascular complications in patients with peripheral arterial disease is unclear.We assigned patients with peripheral arterial disease to combination therapy (...) with an antiplatelet agent and an oral anticoagulant agent (target international normalized ratio [INR], 2.0 to 3.0) or to antiplatelet therapy alone. The first coprimary outcome was myocardial infarction, stroke, or death from cardiovascular causes; the second coprimary outcome was myocardial infarction, stroke, severe ischemia of the peripheral or coronary arteries leading to urgent intervention, or death from cardiovascular causes.A total of 2161 patients were randomly assigned to therapy. The mean follow-up

2007 NEJM Controlled trial quality: predicted high

350. Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial. Full Text available with Trip Pro

Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial. To determine the optimum duration of oral anticoagulant therapy after an episode of deep vein thrombosis or pulmonary embolism, or both.Multicentre, prospective, randomised study with follow-up for one year.46 hospitals in United Kingdom.Patients aged > or =18 with deep vein thrombosis or pulmonary embolism, or both.Three (n=369) or six months (n=380 (...) ) of anticoagulation with heparin for five days accompanied and followed by warfarin, with a target international normalised ratio of 2.0-3.5.Death from deep vein thrombosis or pulmonary embolism; failure to resolve, extension, recurrence of during treatment; recurrence after treatment; and major haemorrhage during treatment.In the patients allocated to three months' treatment two died from deep vein thrombosis or pulmonary embolism during or after treatment, compared with three in the six month group. During

2007 BMJ Controlled trial quality: predicted high

351. Self-testing and self-management of oral anticoagulation - early assessment briefs (Alert)

Self-testing and self-management of oral anticoagulation - early assessment briefs (Alert) Self-testing and self-management of oral anticoagulation - early assessment briefs (Alert) Self-testing and self-management of oral anticoagulation - early assessment briefs (Alert) Swedish Council on Technology Assessment in Health Care Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been (...) made for the HTA database. Citation Swedish Council on Technology Assessment in Health Care. Self-testing and self-management of oral anticoagulation - early assessment briefs (Alert) Stockholm: The Swedish Council on Health Technology Assessment (SBU). SBU Alert report no 2007-05. 2007 Authors' objectives Primary questions: What are the benefits of self-testing and self-management compared to using conventional management (testing and dosing at healthcare facilities) for patients needing long-term

2007 Health Technology Assessment (HTA) Database.

352. Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: a systematic review and economic modelling

Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: a systematic review and economic modelling Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: a systematic review and economic modelling Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: a systematic review and economic modelling Connock M (...) , Stevens C, Fry-Smith A, Jowett S, Fitzmaurice D, Moore D, Song F Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Connock M, Stevens C, Fry-Smith A, Jowett S, Fitzmaurice D, Moore D, Song F. Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: a systematic review and economic

2007 Health Technology Assessment (HTA) Database.

353. An economic model of adverse events and costs for oral anticoagulants used for atrial fibrillation

An economic model of adverse events and costs for oral anticoagulants used for atrial fibrillation An economic model of adverse events and costs for oral anticoagulants used for atrial fibrillation An economic model of adverse events and costs for oral anticoagulants used for atrial fibrillation Leigh J P, White R H Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the clinical and economic impact of warfarin versus a second anticoagulant in hypothetical cohort of 70-year-old patients with atrial fibrillation. There was substantial variation in rates and costs of adverse events when considering all possible scenarios, but the difference in costs between the two drugs was modest. Overall, the analysis

2007 NHS Economic Evaluation Database.

354. Point-of-care monitoring devices for long-term oral anticoagulation therapy: clinical and cost effectiveness

Point-of-care monitoring devices for long-term oral anticoagulation therapy: clinical and cost effectiveness Point-of-care monitoring devices for long-term oral anticoagulation therapy: clinical and cost effectiveness Point-of-care monitoring devices for long-term oral anticoagulation therapy: clinical and cost effectiveness Brown A, Wells P, Jaffey J, McGahan L, Poon M-C, Cimon K, Campbell K Record Status This is a bibliographic record of a published health technology assessment from a member (...) of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Brown A, Wells P, Jaffey J, McGahan L, Poon M-C, Cimon K, Campbell K. Point-of-care monitoring devices for long-term oral anticoagulation therapy: clinical and cost effectiveness. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Technology Report No 72. 2007 Authors' objectives The objectives were to assess the clinical and economic implications of point-of-care (POC) monitoring

2007 Health Technology Assessment (HTA) Database.

355. Ximelagatran/melagatran against conventional anticoagulation: a meta-analysis based on 22,639 patients

Ximelagatran/melagatran against conventional anticoagulation: a meta-analysis based on 22,639 patients Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 DARE.

356. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients

Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients Dentali F, Douketis J D, Gianni M, Lim W, Crowther M A CRD summary This review assessed the effects of anticoagulant prophylaxis (...) in hospitalised medical patients. The authors concluded that anticoagulant prophylaxis is effective in preventing symptomatic venous thromboembolism during anticoagulant prophylaxis in at-risk hospitalised patients. This was a well-conducted review and the authors' conclusions are likely to be reliable. Authors' objectives To determine the effects of anticoagulant prophylaxis in reducing clinically important outcomes in hospitalised medical patients. Searching The authors searched MEDLINE and EMBASE from

2007 DARE.

357. Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardivascular disease: a meta-analysis of randomized trials

Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardivascular disease: a meta-analysis of randomized trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 DARE.

358. A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications

A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 DARE.

359. Self-management of oral anticoagulant therapy: a systematic review and meta-analysis

Self-management of oral anticoagulant therapy: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 DARE.

360. Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials

Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 DARE.